Clinical Trials Directory

Trials / Completed

CompletedNCT03323450

Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Virginia Commonwealth University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To investigate a computer-based Cognitive Remediation Therapy (CRT) for brain tumor patients at the Massey Cancer Center on measures of cognitive functioning (e.g., working memory, attention, processing speed, language, visuospatial functioning, immediate and delayed memory, or executive functioning) over time.

Detailed description

Participants will be recruited by their neuropsychologist in the VCU Massey Cancer Center following standard neuropsychological evaluation (their neuro-oncologist may refer them to this study). If meeting inclusion criteria (described in later sections on participants), participants will be recruited and enrolled in the study. Two groups will be formed: High grade gliomas (WHO grade III or IV; n=15) and Low grade gliomas (WHO grade II; n=15). Participants will be followed over 11 months. The two groups will follow identical study timelines.

Conditions

Interventions

TypeNameDescription
BEHAVIORALCogMed®It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program. Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care): 1. Baseline before the participant is introduced to the CogMed® training program 2. Within 2 weeks of completion of the CogMed® program 3. At 3 months of completion of the CogMed® program to establish maintenance of gains 4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains

Timeline

Start date
2017-10-20
Primary completion
2020-06-01
Completion
2020-06-01
First posted
2017-10-27
Last updated
2020-10-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03323450. Inclusion in this directory is not an endorsement.